 The deal gives Johnson Johnsons Janssen unit access to Momentas experimental therapy, nipocalimab, being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles. Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases, Johnson Johnson said in a statement. JJ reiterated its 2020 adjusted earnings per share forecast and said it expected the deal to close in the second half of 2020. 